212pb tcmc trastuzumab
212pb tcmc trastuzumab - a radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab conjugated with the bifunctional chelating agent tcmc ((1,4,7,10 tetra (2 carbamoyl methyl) cyclododecane), and radiolabeled with the alpha emitting isotope lead pb 212, with potential anti tumor activity. Upon administration, the antibody moiety of lead pb 212 tcmc trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (her2); after internalization, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to the her2 expressing tumor cells. Her2, a tyrosine kinase receptor, is overexpressed on the cell surface of a variety of cancer cell types.
Up to date info
Latest research - 212pb tcmc trastuzumab
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 212pb tcmc trastuzumab for any updates.